Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks.
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock a buy.
Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday
We recently compiled a list of the 10 Companies Echo Friday’s Market Pessimism. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks.
Why Neurocrine Biosciences, Inc.’s (NBIX) Stock Is Down 18.53%
Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time to buy.
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.
Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
Neurocrine Biosciences (($NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences’ earnings call
Neurocrine Biosciences stock falls on revenue miss
Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® (valbenazine) net product sales for the full year of 2024 compared to the previous year,
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today's call will be recorded, and I will be standing by should you need any assistance.
FiercePharma7h
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Mirae Asset Global Investments Co. Ltd. Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 21.8% in the fourth quarter, according to the company in its most ...
Neurocrine price target lowered to $163 from $165 at Guggenheim
Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...
UBS cuts Neurocrine Bio. stock target to $154, maintains Buy rating
UBS analyst Ashwani Verma adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $154 from the previous $176, while continuing to recommend the stock as a Buy. Currently trading at $118 ...
Needham & Company LLC Reaffirms “Hold” Rating for Neurocrine Biosciences (NASDAQ:NBIX)
Needham & Company LLC reiterated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report released on Friday,Benzinga reports. Several other equities ...
Neurocrine (NBIX) Gets a Buy from Evercore ISI
In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...